Policy brief: update on antiretroviral regimens for treating and preventing HIV infection and update on early infant diagnosis of HIV: interim guidance

WHO policy brief

World Health Organization

Since WHO published the 2016 ARV guidelines, several studies have evaluated the safety and efficacy of dolutegravir (DTG) during pregnancy and the periconception period, among children and among people with HIV-associated TB infection. Ample evidence supports using DTG as a preferred first-line ARV drug for everyone living with HIV older than six years and weighing more than 15 kg, including women and adolescent girls of childbearing potential who are using consistent and reliable contraception. DTG has been found to be effective for pregnant women and is found in breast milk, resulting in significant plasma concentration in infants and thus a potential important tool to reduce the mother-to-child transmission of HIV infection. However, an ongoing observational study in Botswana recently identified a signal of potential safety risk for developing neural tube defects among infants born to women who were taking DTG at conception. WHO is taking this potential safety issue seriously and is working closely with all relevant stakeholders, including health ministries, the study investigators, the manufacturer and partner organizations, to further investigate these preliminary findings. Regulatory authorities are also reviewing this matter. WHO will update these data and provide additional information as it becomes available.

In 2016, WHO also recommended that HIV virological testing be used to diagnose HIV infection among infants and children younger than 18 months and that ART be started without delay while a second specimen is collected to confirm the initial positive virological test result. Confirmatory testing of initial positive early infant test results is critical due to the risk of low level viremia, potential contamination with maternal blood, specimen mislabeling, and laboratory contamination. However, the complexity of early infant diagnosis testing is now growing because of the significant scaling up of the “treat all” policy, implementation of enhanced prophylaxis, reduced mother-to-child transmission rates and the increased relative contribution of postnatal transmission. Early infant diagnosis can no longer be a one-test process but now requires additional testing over the duration of exposure. Several additional key considerations are therefore required to strengthen the early infant diagnosis testing cascade. These include repeat testing of indeterminate results in the laboratory, confirmatory testing of all positive test results and testing throughout the exposure period.

July 23, 2018
Year of publication
Resource types
Guidelines and Policies
first-line antiretroviral therapy, dolutegravir, early infant diagnosis (EID), treatment guidelines, DTG, side-effects, virological testing, drug safety

Similar Resources

Initiation of antiretroviral therapy (ART) following diagnosis of HIV infection at birth is an emerging area of paediatric HIV care. We present outcomes of HIV-infected infants identified at birth at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa.

An essential first step in caring for HIV-infected children is accurate and early diagnosis of HIV, early HIV testing, prompt return of results, and rapid initiation of treatment.

Baylor-Malawi, with USAID funding, has developed a special JAIDS supplement featuring 11 articles which highlight lessons and best practices from the Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative, a public-private partnership that expanded pediatric HIV services in nine sub-Saharan

The Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative was a public-private partnership that expanded pediatric HIV services in nine sub-Saharan African countries from 2014-2016, providing treatment to more than 560,000 children living with HIV.

The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics…

PrEP could complement established HIV prevention strategies for pregnant and breastfeeding women as part of a comprehensive package to reduce HIV infections among women and transmission from mothers to infants in settings with high HIV incidence.

This study aimed to evaluate the impact of clinic-based prevention of mother-to-child transmission (PMTCT) community support by trained lay health workers in addition to standard clinical care on PMTCT infant outcomes.

The Pediatric-Adolescent Treatment Africa (PATA) and the Positive Action for Children Fund (PACF) have worked across 9 countries and facilitated 36 clinic-community collaborations through their partnership on the three-year Clinic-CBO Collaboration (C3) Programme, which aims to…

Many countries are working to reduce or eliminate mother-to-child transmission (MTCT) of HIV. Prevention efforts have been conceptualized as steps in a cascade but cascade completion rates during and after pregnancy are low.